ArticleJournal of neuro-oncology2018
Prevalence, risk factors, and response to treatment for hypersomnia of central origin in survivors of childhood brain tumors.
Article in Journal of neuro-oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 2 syntheses or guidelines pooled it, 32 citations in OpenAlex.
- Sleep disorders associated with cranial radiation-A systematic review.Neuro-oncology · 2025Pooled it
- Systematic Review: Sleep Disorders Based on Objective Data in Children and Adolescents Treated for a Brain Tumor.Frontiers in neuroscience · 2022Pooled it
- Secondary narcolepsy and cognitive dysfunction related to craniopharyngioma: a case study.BMC neurology · 2026Article
- A longitudinal assessment of sleep architecture in children and adolescents with craniopharyngioma.Sleep advances : a journal of the Sleep Research Society · 2026Article
- Sleep Disorders, Dysregulation of Circadian Rhythms, and Fatigue After Craniopharyngioma-A Narrative Review.Biomedicines · 2025Review
- Polysomnography analysis of sleep in a cohort of children treated for brain tumour.Child's nervous system : ChNS : official journal of the International Society for Pediatric Neurosurgery · 2025Article
- Sleep disturbances in brain tumors: a narrative review.Frontiers in oncology · 2025Review
- Secondary Narcolepsy as Worsening Sign in a Pediatric Case of Optic Pathway Glioma.Children (Basel, Switzerland) · 2022Article
- Keep Your Mask On: The Benefits of Masking for Behavior and the Contributions of Aging and Disease on Dysfunctional Masking Pathways.Frontiers in neuroscience · 2022Review
- Prevalence of Sleep Disturbances in Pediatric Cancer Patients and Their Diagnosis and Management.Children (Basel, Switzerland) · 2021Review
- Height, weight, and cardiovascular effects of stimulants on children with brain tumors.Pediatric blood & cancer · 2021Article
- Sleep Disorders in Patients With Craniopharyngioma: A Physiopathological and Practical Update.Frontiers in neurology · 2021Review
- Excessive daytime sleepiness due to brain tumor.Journal of clinical sleep medicine : JCSM : official publication of the American Academy of Sleep Medicine · 2020Article
- Predictors of narcolepsy and hypersomnia due to medical disorder in pediatric craniopharyngioma.Journal of neuro-oncology · 2020Article
- Guidelines for Treatment and Monitoring of Adult Survivors of Pediatric Brain Tumors.Current treatment options in oncology · 2019Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors at 2 institutions in 1 country.
Funding
Abstract
Daytime sleepiness is recognized in childhood brain tumor survivors. Our objective was to determine prevalence, risk factors for PSG/MLST proven hypersomnia/narcolepsy, and response to stimulants in childhood brain tumor survivors. Standard PSG/MSLT criteria were used to diagnose hypersomnia/narcolepsy. Medical records of brain tumor survivors having undergone a PSG/MSLT were reviewed for the diagnostic code of hypersomnia/narcolepsy. Survivors with hypersomnia/narcolepsy were matched with 2-3 survivors without reported hypersomnia/narcolepsy by age at tumor diagnosis, gender, and time from tumor diagnosis. Between January 2000 to April 2015, 39 of the 2336 brain tumor patients treated at our institution were diagnosed with hypersomnia/narcolepsy for a prevalence rate of 1670/100,000. Hypersomnia/narcolepsy was diagnosed at a median of 6.1 years (range 0.4-13.2) from tumor diagnosis and 4.7 years (range - 1.5 to 10.4) from cranial radiation. Midline tumor location (OR 4.6, CI 1.7-12.2, p = 0.002) and anti-epilepsy drug (AED) use (OR 11, CI 2.4-54) correlated with hypersomnia/narcolepsy while radiation dose > 30 Gray trended towards significance (OR 1.8, CI 0.9-3.6); posterior fossa tumor location reduced the risk (OR 0.1, CI 0.04-0.5, p = 0.002). AED use also correlated with midline tumor location. Thirty-seven survivors were treated with stimulants and reported improved wakefulness and school performance [response rate CI 0.97 (0.86-0.99) and 0.83 (0.65-0.94)]. Prevalence of hypersomnia/narcolepsy among childhood brain tumor survivors was higher than the general population. Tumor location and radiation dose were possible risk factors, and stimulants were reported to be beneficial.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.